- Home
- SGMO vs ARCT Comparison
SGMO vs ARCT Comparison
Compare SGMO & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMO
- ARCT
- Stock Information
- Founded
- SGMO 1995
- ARCT 2013
- Country
- SGMO United States
- ARCT United States
- Employees
- SGMO N/A
- ARCT N/A
- Industry
- SGMO Biotechnology: Biological Products (No Diagnostic Substances)
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- SGMO Health Care
- ARCT Health Care
- Exchange
- SGMO Nasdaq
- ARCT Nasdaq
- Market Cap
- SGMO 488.2M
- ARCT 487.0M
- IPO Year
- SGMO 2000
- ARCT N/A
- Fundamental
- Price
- SGMO $1.13
- ARCT $16.41
- Analyst Decision
- SGMO Buy
- ARCT Strong Buy
- Analyst Count
- SGMO 5
- ARCT 7
- Target Price
- SGMO $5.20
- ARCT $65.00
- AVG Volume (30 Days)
- SGMO 10.5M
- ARCT 375.2K
- Earning Date
- SGMO 03-12-2025
- ARCT 03-06-2025
- Dividend Yield
- SGMO N/A
- ARCT N/A
- EPS Growth
- SGMO N/A
- ARCT N/A
- EPS
- SGMO N/A
- ARCT N/A
- Revenue
- SGMO $52,291,000.00
- ARCT $160,399,000.00
- Revenue This Year
- SGMO N/A
- ARCT $7.33
- Revenue Next Year
- SGMO $5.97
- ARCT $4.71
- P/E Ratio
- SGMO N/A
- ARCT N/A
- Revenue Growth
- SGMO N/A
- ARCT N/A
- 52 Week Low
- SGMO $0.30
- ARCT $14.30
- 52 Week High
- SGMO $3.18
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- SGMO 37.01
- ARCT 44.15
- Support Level
- SGMO $1.00
- ARCT $16.07
- Resistance Level
- SGMO $1.18
- ARCT $17.51
- Average True Range (ATR)
- SGMO 0.15
- ARCT 1.36
- MACD
- SGMO -0.04
- ARCT -0.11
- Stochastic Oscillator
- SGMO 13.84
- ARCT 7.62
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.